Logo image of VSTM

VERASTEM INC (VSTM) Stock Fundamental Analysis

NASDAQ:VSTM - US92337C2035 - Common Stock

9.25 USD
+0.02 (+0.22%)
Last: 8/29/2025, 8:00:02 PM
9.17 USD
-0.08 (-0.86%)
After Hours: 8/29/2025, 8:00:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to VSTM. VSTM was compared to 542 industry peers in the Biotechnology industry. Both the profitability and financial health of VSTM have multiple concerns. While showing a medium growth rate, VSTM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VSTM had negative earnings in the past year.
VSTM had a negative operating cash flow in the past year.
VSTM had negative earnings in each of the past 5 years.
In the past 5 years VSTM always reported negative operating cash flow.
VSTM Yearly Net Income VS EBIT VS OCF VS FCFVSTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

With a Return On Assets value of -66.56%, VSTM is not doing good in the industry: 60.15% of the companies in the same industry are doing better.
VSTM has a Return On Equity of -362.32%. This is in the lower half of the industry: VSTM underperforms 73.99% of its industry peers.
Industry RankSector Rank
ROA -66.56%
ROE -362.32%
ROIC N/A
ROA(3y)-88.21%
ROA(5y)-74.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VSTM Yearly ROA, ROE, ROICVSTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VSTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VSTM Yearly Profit, Operating, Gross MarginsVSTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

VSTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
VSTM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VSTM has been increased compared to 5 years ago.
The debt/assets ratio for VSTM is higher compared to a year ago.
VSTM Yearly Shares OutstandingVSTM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
VSTM Yearly Total Debt VS Total AssetsVSTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -6.36, we must say that VSTM is in the distress zone and has some risk of bankruptcy.
VSTM has a worse Altman-Z score (-6.36) than 65.50% of its industry peers.
VSTM has a Debt/Equity ratio of 2.25. This is a high value indicating a heavy dependency on external financing.
VSTM's Debt to Equity ratio of 2.25 is on the low side compared to the rest of the industry. VSTM is outperformed by 80.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.25
Debt/FCF N/A
Altman-Z -6.36
ROIC/WACCN/A
WACC9.99%
VSTM Yearly LT Debt VS Equity VS FCFVSTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

VSTM has a Current Ratio of 3.46. This indicates that VSTM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.46, VSTM is in line with its industry, outperforming 40.77% of the companies in the same industry.
A Quick Ratio of 3.44 indicates that VSTM has no problem at all paying its short term obligations.
The Quick ratio of VSTM (3.44) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.44
VSTM Yearly Current Assets VS Current LiabilitesVSTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.89% over the past year.
The Revenue for VSTM have been decreasing by -10.55% on average. This is quite bad
EPS 1Y (TTM)6.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.81%
Revenue 1Y (TTM)N/A
Revenue growth 3Y69.6%
Revenue growth 5Y-10.55%
Sales Q2Q%-78.63%

3.2 Future

VSTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.46% yearly.
The Revenue is expected to grow by 123.50% on average over the next years. This is a very strong growth
EPS Next Y22.19%
EPS Next 2Y18.22%
EPS Next 3Y17.01%
EPS Next 5Y20.46%
Revenue Next Year103.81%
Revenue Next 2Y217.7%
Revenue Next 3Y188.05%
Revenue Next 5Y123.5%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VSTM Yearly Revenue VS EstimatesVSTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
VSTM Yearly EPS VS EstimatesVSTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VSTM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VSTM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VSTM Price Earnings VS Forward Price EarningsVSTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VSTM Per share dataVSTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

VSTM's earnings are expected to grow with 17.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.22%
EPS Next 3Y17.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VSTM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERASTEM INC

NASDAQ:VSTM (8/29/2025, 8:00:02 PM)

After market: 9.17 -0.08 (-0.86%)

9.25

+0.02 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04
Inst Owners84.73%
Inst Owner Change24.8%
Ins Owners0.62%
Ins Owner Change-1.19%
Market Cap569.34M
Analysts85.33
Price Target15.43 (66.81%)
Short Float %34.24%
Short Ratio6.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.76%
Min EPS beat(2)-8.89%
Max EPS beat(2)48.42%
EPS beat(4)2
Avg EPS beat(4)-0.42%
Min EPS beat(4)-61.48%
Max EPS beat(4)48.42%
EPS beat(8)4
Avg EPS beat(8)-0.76%
EPS beat(12)7
Avg EPS beat(12)1.59%
EPS beat(16)8
Avg EPS beat(16)-2.55%
Revenue beat(2)1
Avg Revenue beat(2)-6.6%
Min Revenue beat(2)-100%
Max Revenue beat(2)86.8%
Revenue beat(4)1
Avg Revenue beat(4)-53.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)86.8%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.82%
PT rev (3m)13.08%
EPS NQ rev (1m)7.34%
EPS NQ rev (3m)3.14%
EPS NY rev (1m)11.52%
EPS NY rev (3m)-5.35%
Revenue NQ rev (1m)19.61%
Revenue NQ rev (3m)87.49%
Revenue NY rev (1m)19.55%
Revenue NY rev (3m)-10.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 56.93
P/FCF N/A
P/OCF N/A
P/B 15.79
P/tB 27.88
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-2.11
Fwd EYN/A
FCF(TTM)-1.95
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS0.16
BVpS0.59
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.56%
ROE -362.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.21%
ROA(5y)-74.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 2.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.44
Altman-Z -6.36
F-Score5
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)35.9%
Cap/Depr(5y)41.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.81%
EPS Next Y22.19%
EPS Next 2Y18.22%
EPS Next 3Y17.01%
EPS Next 5Y20.46%
Revenue 1Y (TTM)N/A
Revenue growth 3Y69.6%
Revenue growth 5Y-10.55%
Sales Q2Q%-78.63%
Revenue Next Year103.81%
Revenue Next 2Y217.7%
Revenue Next 3Y188.05%
Revenue Next 5Y123.5%
EBIT growth 1Y-24.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5Y36.99%
FCF growth 1Y-67.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.27%
OCF growth 3YN/A
OCF growth 5YN/A